AstraZeneca Q1 2026 Results: Strong Revenue Growth and Positive Pipeline Readouts

AstraZeneca Q1 2026 results analysis – strong sales growth backed by Oncology and Rare Disease

AstraZeneca has opened 2026 with a solid set of numbers. Total Revenue came in at $15,288 million, up 13% on a reported basis and up 8% at CER – that is constant exchange rates, which strips out currency swings and gives a cleaner view of underlying growth.

For me, the headline is straightforward: the business is still growing well, the drug pipeline is still delivering, and management is confident enough to reconfirm full-year guidance. That is exactly what investors usually want from a big pharma update.

Key Q1 2026 numbers	Result	Change
Total Revenue	$15,288 million	Up 13% reported, up 8% CER
Product Revenue	$15,211 million	Up 13% reported, up 8% CER
Reported EPS	$1.99	Up 6% reported, up 8% CER
Core EPS	$2.58	Up 4% reported, up 5% CER
Core operating profit	$5,352 million	Up 11% reported, up 12% CER
Core tax rate	21%	Prior year was 16%

There is one small wrinkle in an otherwise strong quarter. Core EPS – earnings per share on AstraZeneca’s preferred adjusted basis – only grew 5% at CER, which is slower than revenue growth. The company says that reflects a favourable tax rate in the prior year period, so this looks more like a comparison issue than a sign of weakening demand.

Oncology and Rare Disease were the engines of AstraZeneca revenue growth in Q1 2026

The best part of the update is where the growth came from. Oncology revenue reached $6,798 million, up 20% reported and 16% at CER, while Rare Disease brought in $2,420 million, up 19% reported and 15% at CER.

That matters because these are high-value therapy areas with strong competitive positions. In plain English, AstraZeneca is making more money from the bits of the portfolio that investors tend to value most highly.

Top medicine performers in the AstraZeneca Q1 2026 results

• Imfinzi revenue rose to $1,694 million, up 34% reported and 30% CER.
• Enhertu revenue rose to $831 million, up 40% reported and 34% CER.
• Tagrisso revenue reached $1,833 million, up 9% reported and 5% CER.
• Ultomiris revenue climbed to $1,270 million, up 21% reported and 18% CER.
• Strensiq revenue jumped to $517 million, up 47% reported and 43% CER.
• Tezspire revenue increased to $303 million, up 40% reported and 34% CER.

This is a healthy mix. AstraZeneca is not leaning on one miracle drug. It has growth coming from cancer, rare disease and respiratory products, which makes the story more durable.

Where the weak spots showed up

Not every division had a great quarter. Cardiovascular, Renal & Metabolism Product Revenue was $3,241 million, flat on a reported basis and down 7% at CER, with Farxiga, Brilinta and roxadustat all facing generic competition or pricing pressure.

Brilinta was particularly ugly, down 65% reported and 67% CER to $105 million. Farxiga still generated $2,193 million of Product Revenue, but CER growth was negative at 2%, held back by generic competition and volume-based procurement in China.

Infectious Disease also looked soft, with Product Revenue of $182 million, down 19% reported and 22% CER. So yes, the quarter was strong overall, but it was not flawless.

AstraZeneca pipeline update – tozorakimab and efzimfotase alfa are the real excitement

This is where the RNS gets genuinely interesting. AstraZeneca flagged positive readouts for four high-value Phase III programmes since the Q4 2025 results, including for two NMEs – new molecular entities, which is pharma speak for brand-new medicine candidates.

The standout names are tozorakimab in COPD and efzimfotase alfa in hypophosphatasia, or HPP. New blockbuster candidates are what keep large pharma growth stories alive, and AstraZeneca clearly wants investors focused on that.

What went well in the pipeline

• tozorakimab met the primary endpoint in OBERON, TITANIA and MIRANDA in COPD.
• efzimfotase alfa met the primary endpoint in MULBERRY and CHESTNUT in HPP.
• Ultomiris met the primary endpoint in I CAN for IgAN.
• Imfinzi met the primary endpoint in EMERALD-3.
• The company also recorded 14 approvals in major regions since the Q4 2025 results.

That is a strong read-through for future growth. It suggests the current product portfolio is not the whole story – AstraZeneca is still feeding the machine.

What did not go to plan

It was not all clean wins. Imfinzi plus Orpathys missed the primary endpoint in SAMETA, tozorakimab did not meet the primary endpoint in PROSPERO, efzimfotase alfa missed in HICKORY, and ARTEMIS for Ultomiris was discontinued due to inconsistent efficacy.

That is normal in drug development, but it is still worth noting. The overall pipeline picture is positive, though investors should not pretend every programme is landing perfectly.

AstraZeneca guidance for FY 2026 stays intact – a reassuring signal for shareholders

Management reconfirmed its 2026 guidance. AstraZeneca still expects Total Revenue to increase by a mid-to-high single-digit percentage at CER, and Core EPS to increase by a low double-digit percentage.

That matters more than it might seem. When a company reports a decent quarter and keeps guidance unchanged, it usually means management sees enough momentum ahead to stay comfortable. In this case, it supports Pascal Soriot’s message that AstraZeneca remains on track for its 2030 ambition.

Cash flow, net debt and the CSPC obesity deal – strong business, but spending is rising

There is a cost to building a bigger pharma business. Net cash inflow from operating activities fell to $3,359 million from $3,713 million, while net cash outflow from investing activities increased to $1,792 million from $1,253 million.

Net debt increased by $2,570 million in the quarter to $25,944 million. Capital expenditure was $645 million, up from $493 million, and the company expects FY 2026 spending on property, plant and equipment and software-related intangible assets to rise by approximately a third.

Then there is the April 2026 CSPC deal. AstraZeneca closed its obesity and type 2 diabetes collaboration with an upfront payment of $1.2 billion, with the majority due to be capitalised in Q2 2026. Strategically, I like the move because obesity is one of the hottest areas in pharma, but it does underline that AstraZeneca is spending aggressively to stay ahead.

What AstraZeneca Q1 2026 results mean for retail investors

My read is positive. The quarter shows strong underlying demand, especially in Oncology and Rare Disease, and the pipeline is adding fresh reasons for optimism. That combination is powerful.

The negatives are manageable rather than alarming. Some mature drugs are clearly under pressure from generics, Core EPS growth was held back by tax, and debt has moved higher. But none of that breaks the investment case laid out in this announcement.

If you own AstraZeneca shares, this looks like the kind of update you would want to see from a premium pharma name – good sales growth, meaningful pipeline progress, plenty of approvals, and full-year guidance left untouched. In short, the engine still looks in good working order.